IP Library Granted Patent US 7,307,094
Granted Patent B2
US 7,307,094 · App. 11/357,494 · Granted Dec 11, 2007

Benzoxazole carboxamides for treating CINV and IBS-D

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,307,094
App. No.
11/357,494
Granted
Dec 11, 2007
Kind
B2
Abstract

Compounds of formulae I and II: are disclosed as 5-HT 3 inhibitors. Those compounds that exhibit central activity are useful in treating CINV; those that inhibit peripheral receptors are useful to treat IBS-D.

Claims (224)

1. A compound of formula

wherein

R 1 , R 2 and R 3 are independently selected from hydrogen, halogen, amino, alkylamino, dialkylamino, acylamino, morpholinyl, —O-loweralkyl, hydroxy, loweralkyl, fluoroloweralkyl, —O-lowerfluoroalkyl, methylenedioxy, ethylenedioxy, alkoxy-loweralkyl and hydroxyloweralkyl;

R 4 is a saturated nitrogen heterocycle or methyl-substituted saturated nitrogen heterocycle, in which said nitrogen is tertiary, said heterocycle containing at least one 5 or 6-membered ring; and

Ar is chosen from the group consisting of

(i) aryl;

(ii) heteroaryl;

(iii) substituted aryl;

(iv) substituted heteroaryl; and

(v) dihydroheteroaryl.

2. A compound according to claim 1 of formula

wherein

R 1 , R 2 and R 3 are independently selected from hydrogen, halogen, amino, alkylamino, dialkylamino, acylamino, morpholinyl, —O-loweralkyl, hydroxy, loweralkyl, fluoroloweralkyl, —O-lowerfluoroalkyl, methylenedioxy, ethylenedioxy, alkoxy-loweralkyl and hydroxyloweralkyl;

represents a saturated nitrogen heterocycle or methyl-substituted saturated nitrogen heterocycle, in which said nitrogen is tertiary, said heterocycle containing at least one 5 or 6-membered ring; and

Ar is chosen from the group consisting of:

(i) aryl;

(ii) heteroaryl other than 2-pyridinyl and 3-pyridinyl, provided that when

is methyl azabicyclo[3.3.1]nonane, Ar may additionally be 3-pyridinyl;

(iii) aryl substituted with from one to four substitutents chosen from lower alkoxy, phenoxy, trialkylsilylacetylenyl, anilino, lower alkynyl, lower alkyl, halogen, nitro, cyano, hydroxy, amino, methylenedioxy, alkylamino, dialkylamino, phenyl, heterocyclyl, methylheterocyclyl, methylenedioxy and acylamino;

(iv) heteroaryl substituted with one or two substitutents chosen from oxo, halogen, and alkyl; and

(v) dihydroheteroaryl;

with the proviso that, when Ar is phenyl and

is 1-azabicyclo[2.2.2]oct-3-yl, R 2 cannot be chloro.

3. A compound of formula

wherein

R 1 , R 2 and R 3 are independently selected from hydrogen, halogen, amino, alkylamino, dialkylamino, acylamino, morpholinyl, —O-loweralkyl, hydroxy, loweralkyl, fluoroloweralkyl, —O-lowerfluoroalkyl, methylenedioxy, ethylenedioxy, alkoxy-loweralkyl and hydroxyloweralkyl;

R 4 is a saturated nitrogen heterocycle or methyl-substituted saturated nitrogen heterocycle, in which said nitrogen is tertiary, said heterocycle containing at least one 5 or 6-membered ring; and

Ar is chosen from the group consisting of

(i) aryl;

(ii) heteroaryl;

(iii) substituted aryl;

(iv) substituted heteroaryl; and

(v) dihydroheteroaryl.

4. A compound according to claim 3 of formula

wherein

R 1 , R 2 and R 3 are independently selected from hydrogen, halogen, amino, alkylamino, dialkylamino, acylamino, morpholinyl, —O-loweralkyl, hydroxy, loweralkyl, fluoroloweralkyl, —O-lowerfluoroalkyl, methylenedioxy, ethylenedioxy, alkoxy-loweralkyl and hydroxyloweralkyl;

represents a saturated nitrogen heterocycle or methyl-substituted saturated nitrogen heterocycle, in which said nitrogen is tertiary, said heterocycle containing at least two 6-membered rings; and

Ar is chosen from the group consisting of

(i) aryl;

(ii) heteroaryl other than 2-pyridinyl and 3-pyridinyl;

(iii) aryl substituted with from one to four substitutents chosen from lower alkoxy, phenoxy, trialkylsilylacetylenyl, anilino, lower alkynyl, lower alkyl, halogen, nitro, cyano, hydroxy, amino, acetylamino, methylenedioxy, alkylamino, dialkylamino, phenyl, heterocyclyl, methylheterocyclyl, methylenedioxy and acylamino;

(iv) heteroaryl substituted with one or two substitutents chosen from oxo, halogen, and alkyl; and

(v) dihydroheteroaryl;

with the proviso that, when

is 1-azabicyclo[2.2.2]oct-3-yl and all of R 1 , R 2 and R 3 are H, Ar cannot be phenyl or phenyl substituted with halogen.

5. A compound according to claim 2 wherein

is chosen from:

wherein

m=1, 2, 3 or 4;

n=0, 1, 2, 3 or 4; and

R 5 is hydrogen or methyl.

6. A compound according to claim 4 wherein

is chosen from:

wherein

m=1, 2, 3 or 4;

n=0, 1, 2, 3 or 4; and

R 5 is hydrogen or methyl.

7. A compound according to claim 5 wherein

is chosen from quinuclidine, tropane, azabicyclo[3.3.1]nonane and methyl azabicyclo[3.3.1]nonane.

8. A compound according to claim 6 wherein

is chosen from quinuclidine, tropane, azabicyclo[3.3.1]nonane and methyl azabicyclo[3.3.1]nonane.

9. A compound according to claim 1 or 3 , wherein R 1 , R 2 and R 3 are hydrogen.

10. A compound according to claim 1 or 3 , wherein one of R 1 , R 2 and R 3 is halogen.

11. A compound according to claim 1 or 3 , wherein R 1 and R 3 are hydrogen and R 2 is chosen from amino, halogen, methoxy, hydroxy, acetylamino, and 4-morpholinyl.

12. A compound according to claim 1 or 3 wherein Ar is chosen from the group consisting of phenyl and phenyl substituted with from 1 to 4 groups independently selected from (C 1 to C 4 )alkyl, phenyl, phenoxy, halogen, (C 1 to C 4 )alkoxy, amino, (C 1 to C 4 )alkylamino, di(C 1 to C 4 )alkylamino, anilino, heterocyclyl, methylheterocyclyl, methylenedioxy, (C 1 to C 4 )acylamino, (C 1 to C 4 )alkynyl and nitro.

13. A compound according to claim 12 wherein Ar is chosen from the group consisting of phenyl and phenyl substituted with one or two residues chosen independently from (C 1 to C 4 )alkyl, 4-methylpiperazinl-yl, morpholin-4-yl, pyridin-4-yl, phenyl, phenoxy, amino, anilino, halogen, methoxy, dimethylamino, methylenedioxy, acetylamino, propyn-1-yl and nitro.

14. A compound according to claim 1 or 3 wherein Ar is chosen from the group consisting of heteroaryl, dihydroheteroaryl and substituted heteroaryl.

15. A compound according to claim 14 wherein Ar is chosen from thiophene, cyclopenta[b]thiophene, furan, thiazole, isoxazole dihydrobenzofuran, benzofuran, pyridine, benzothiophene, 3-pyridine-2-one, and their methylated and halogenated congeners.

16. A compound according to claim 1 or 3 chosen from the group consisting of:

N-(1-Methylpiperidin-4-yl)-2-phenylbenzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-phenylbenzoxazole-4-carboxamide,

N-(8-Methyl-8-azabicyclo[3.2.1]oct-3-yl)-2-phenylbenzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-6-chloro-2-phenylbenzoxazole-4-carboxamide,

N-(Piperidin-4-yl)-2-phenylbenzoxazole-4-carboxamide,

N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-phenylbenzoxazole-4-carboxamide,

N-(1-Methyl-piperidin-4-yl)-6-chloro-2-phenylbenzoxazole-4-carboxamide,

N-(1-Azabicyclo[2.2.2]oct-3-yl)-6-chloro-2-phenylbenzoxazole-4-carboxamide,

N-(8-Methyl-8-azabicyclo[3.2.1]oct-3-yl)-6-chloro-2-phenylbenzoxazole-4-carboxamide,

N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-(4-chlorophenyl)benzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(4-chlorophenyl)benzoxazole-4-carboxamide,

N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-(4-methoxyphenyl)benzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(4-methoxyphenyl)benzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(4-fluorophenyl)benzoxazole-4-carboxamide,

N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-(4-fluorophenyl)benzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-phenylbenzoxazole-7-carboxamide,

N-(1-Methylpiperidin-4-yl)-2-phenylbenzoxazole-7-carboxamide,

N-(Piperidin-4-yl)-2-phenylbenzoxazole-7-carboxamide,

N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-phenylbenzoxazole-7-carboxamide,

N-(8-Methyl-8-azabicyclo[3.2.1]oct-3-yl)-2-phenylbenzoxazole-7-carboxamide,

N-(1-Azabicyclo[2.2.2]oct-3-yl)-5-chloro-2-phenyl-benzoxazole-7-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-5-chloro-2-phenyl-benzoxazole-7-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(4-fluorophenyl)benzoxazole-7-carboxamide,

N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-(4-methoxyphenyl)benzoxazole-7-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(4-methoxyphenyl)benzoxazole-7-carboxamide,

N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-(4-chlorophenyl)benzoxazole-7-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(4-chlorophenyl)benzoxazole-7-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-phenylbenzothiazole-7-carboxamide,

(S)-N-(1-Azabicyclo[2.2.2]oct-3-yl)-6-chloro-2-phenylbenzoxazole-4-carboxamide,

N-(9-Methyl-3-oxa-9-azabicyclo[3.3.1]non-7-yl)-2-phenylbenzoxazole-4-carboxamide,

N-(9-Methyl-3-oxa-9-azabicyclo[3.3.1]non-7-yl)-6-chloro-2-phenylbenzoxazole-4-carboxamide,

N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-(2-methoxyphenyl)benzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(2-methoxyphenyl)benzoxazole-4-carboxamide Hydrochloride,

N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-(3-methoxyphenyl)benzoxazole-4-carboxamide,

(S)-N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-(2-hydroxyphenyl)benzoxazole-4-carboxamide, Hydrochloride,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(2-hydroxyphenyl)benzoxazole-4-carboxamide Hydrochloride,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(2-bromophenyl)benzoxazole-4-carboxamide Hydrochloride,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(2-aminophenyl)benzoxazole-4-carboxamide Dihydrochloride,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(biphenyl-2-yl)benzoxazole-4-carboxamide Hydrochloride,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(2-pyridine-4-yl)phenylbenzoxazole-4-carboxamide Dihydrochloride,

N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-p-tolylbenzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-p-tolylbenzoxazole-4-carboxamide,

N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-(4-nitrophenyl)benzoxazole-4-carboxamide,

N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-(4-aminophenyl)benzoxazole-4-carboxamide,

N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-(4-acetylaminophenyl)benzoxazole-4-carboxamide,

N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-(4-dimethylaminophenyl)benzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(4-dimethylaminophenyl)benzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(2-dimethylaminophenyl)benzoxazole-4-carboxamide,

(S)-N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-(2-dimethylaminophenyl)benzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-6-chloro-2-(2-dimethylaminophenyl)benzoxazole-4-carboxamide,

(S)-N-(1-Azabicyclo[2.2.2]oct-3-yl)-6-chloro-2-(2-dimethylaminophenyl)benzoxazole-4-carboxamide,

N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-(4-cyanophenyl)benzoxazole-4-carboxamide,

N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-(4-iodophenyl)benzoxazole-4-carboxamide,

N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-(4-trimethylsilylethynylphenyl)benzoxazole-4-carboxamide,

N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-(4-propyn-1-ylphenyl)benzoxazole-4-carboxamide,

N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-(4-ethynylphenyl)benzoxazole-4-carboxamide,

N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-biphenyl-4-ylbenzoxazole-4-carboxamide,

N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-(4-phenoxyphenyl)benzoxazole-4-carboxamide,

N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-(4-phenylaminophenyl)benzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-benzo[1,3]dioxol-5-ylbenzoxazole-4-carboxamide,

(S)-N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-benzo[1,3]dioxol-5-yl-benzoxazole-4-carboxamide,

N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-benzofuran-5-ylbenzoxazole-4-carboxamide,

N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-(2,3-dihydrobenzofuran-5-yl)benzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(2,4-dimethoxyphenyl)benzoxazole-4-carboxamide,

(S)-N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-(2,4-dimethoxyphenyl)benzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(2,4-dichlorophenyl)benzoxazole-4-carboxamide,

(S)-N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-(2,4-dichlorophenyl)benzoxazole-4-carboxamide,

(S)-N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-(4-chloro-2-methoxyphenyl)benzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(4-chloro-2-methoxyphenyl)benzoxazole-4-carboxamide,

(S)-N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-(4-methoxy-2-methylphenyl)benzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(4-methoxy-2-methylphenyl)benzoxazole-4-carboxamide,

(S)-N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-(4-chloro-2-methylphenyl)benzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(4-chloro-2-methylphenyl)benzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl-2-(2,6-dimethylphenyl)benzoxazole-4-carboxamide,

(S)-N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-(2,6-dichlorophenyl)benzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(2,6-dichlorophenyl)benzoxazole-4-carboxamide,

N-(1-Azabicyclo[2.2.2]oct-3-yl)-6-chloro-2-p-tolylbenzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-6-chloro-2-p-tolylbenzoxazole-4-carboxamide,

N-(1-Azabicyclo[2.2.2]oct-3-yl)-6-chloro-2-(4-methoxyphenyl)benzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-6-chloro-2-(4-methoxyphenyl)benzoxazole-4-carboxamide,

N-(1-Azabicyclo[2.2.2]oct-3-yl)-6-bromo-2-phenylbenzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-6-bromo-2-phenylbenzoxazole-4-carboxamide,

N-(1-Azabicyclo[2.2.2]oct-3-yl)-6-bromo-2-p-tolylbenzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-6-bromo-2-p-tolylbenzoxazole-4-carboxamide,

N-(1-Azabicyclo[2.2.2]oct-3-yl)-6-bromo-2-(4-methoxyphenyl)benzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-6-bromo-2-(4-methoxyphenyl)benzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-6-amino-2-phenylbenzoxazole-4-carboxamide Dihydrochloride,

N-(1-Azabicyclo[2.2.2]oct-3-yl)-5-bromo-2-phenylbenzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-5-bromo-2-phenylbenzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-7-bromo-2-phenylbenzoxazole-4-carboxamide,

N-(1-Azabicyclo[2.2.2]oct-3-yl)-7-bromo-2-phenylbenzoxazole-4-carboxamide,

N-(1-Azabicyclo[2.2.2]oct-3-yl)-6-iodo-2-phenylbenzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-6-iodo-2-phenylbenzoxazole-4-carboxamide,

N-(1-Azabicyclo[2.2.2]oct-3-yl)-6-morpholine-2-phenylbenzoxazole-4-carboxamide,

N-(1-Azabicyclo[2.2.2]oct-3-yl)-6-amino-2-phenylbenzoxazole-4-carboxamide,

N-(1-Azabicyclo[2.2.2]oct-3-yl)-6-acetylamino-2-phenylbenzoxazole-4-carboxamide,

(S)-N-(1-Azabicyclo[2.2.2]oct-3-yl)-6-methoxy-2-phenylbenzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-6-methoxy-2-phenylbenzoxazole-4-carboxamide,

(S)-N-(1-Azabicyclo[2.2.2]oct-3-yl)-6-hydroxy-2-phenylbenzoxazole-4-carboxamide,

(S)-N-(1-Azabicyclo[2.2.2]oct-3-yl)-6-fluoro-2-phenylbenzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-6-fluoro-2-phenyl)benzoxazole-4-carboxamide,

(S)-N-(1-Azabicyclo[2.2.2]oct-3-yl)-6-fluoro-2-(2-methoxyphenyl)benzoxazole-4-carboxamide Hydrochloride,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-6-fluoro-2-(2-methoxyphenyl)benzoxazole-4-carboxamide, Hydrochloride,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-pyridin-4-ylbenzoxazole-4-carboxamide,

(S)-N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-furan-2-ylbenzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-furan-2-ylbenzoxazole-4-carboxamide,

(S)-N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-thiophen-2-ylbenzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-thiophen-2-ylbenzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-6-chloro-2-thiophen-2-ylbenzoxazole-4-carboxamide,

(S)-N-(1-Azabicyclo[2.2.2]oct-3-yl)-6-chloro-2-thiophen-2-ylbenzoxazole-4-carboxamide,

(S)-N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-thiophen-3-ylbenzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-thiophen-3-ylbenzoxazole-4-carboxamide,

N-(9-Methyl-3-oxa-9-azabicyclo[3.3.1]non-7-yl)-6-chloro-2-thiophen-3-ylbenzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-6-chloro-2-thiophen-3-ylbenzoxazole-4-carboxamide,

(S)-N-(1-Azabicyclo[2.2.2]oct-3-yl)-6-chloro-2-thiophen-3-ylbenzoxazole-4-carboxamide,

(S)-N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-benzo[b]thiophen-2-ylbenzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-benzo[b]thiophen-2-yl benzoxazole-4-carboxamide,

(S)-N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-benzofuran-2-ylbenzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-benzofuran-2-ylbenzoxazole-4-carboxamide,

(S)-N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-(3-methylthiophen-2-yl)benzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(3-methylthiophen-2-yl)benzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-6-chloro-2-(3-methylthiophen-2-yl)benzoxazole-4-carboxamide,

(S)-N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-(3-chlorothiophen-2-yl)benzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(3-chlorothiophen-2-yl)benzoxazole-4-carboxamide,

(S)-N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-(3-bromothiophen-2-yl)benzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(3-bromothiophen-2-yl)benzoxazole-4-carboxamide,

(S)-N-(1-Azabicyclo[2.2.2]oct-3-yl)-6-chloro-2-(3-chlorothiophen-2-yl)benzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-6-chloro-2-(3-chlorothiophen-2-yl)benzoxazole-4-carboxamide,

(S)-N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-(5-methylthiophen-2-yl)benzoxazole-4-carboxamide,

(S)-N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-(5-chloro-thiophen-2-yl)benzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(5-chlorothiophene-2-yl)benzoxazole-4-carboxamide,

(S)-N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-(5-bromothiophene-2-yl)benzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(5-bromothiophene-2-yl)benzoxazole-4-carboxamide,

(S)-N-(1-Azabicyclo[2.2.2]oct-3-yl)-6-chloro-2-(5-methylthiophen-2-yl)benzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-6-chloro-2-(5-methylthiophen-2-yl)benzoxazole-4-carboxamide,

(S)-N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-(5,6-dihydro-4H-cyclopenta[b]thiophen-2-yl)benzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(5,6-dihydro-4H-cyclopenta[b]thiophen-2-yl)benzoxazole-4-carboxamide,

(S)-N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-(3,5-dimethylisoxazole-4-yl)benzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(3,5-dimethylisoxazole-4-yl)benzoxazole-4-carboxamide,

(S)-N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-(4-methylthiazol-5-yl)benzoxazole-4-carboxamide, Hydrochloride,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(4-methylthiazol-5-yl)benzoxazole-4-carboxamide Hydrochloride,

(S)-N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-(thiazole-4-yl)benzoxazole-4-carboxamide, Hydrochloride

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(thiazol-4-yl)benzoxazole-4-carboxamide Hydrochloride,

(S)-N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-(2-oxo-1,2-dihydropyridin-3-yl)benzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(2-oxo-1,2-dihydropyridin-3-yl)benzoxazole-4-carboxamide,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(2-morpholinophenyl)benzoxazole-4-carboxamide Maleate,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-[2-(4-methylpiperazin-1-yl)phenyl]benzoxazole-4-carboxamide Maleate,

N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(2-isopropylphenyl)benzoxazole-4-carboxamide Hydrochloride, and

(S)-N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-(2-isopropylphenyl)benzoxazole-4-carboxamide Hydrochloride.

17. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to claim 1 or 3 .

18. A pharmaceutical composition according to claim 17 additionally comprising a second antiemetic agent.

19. A pharmaceutical composition according to claim 18 wherein said second antiemetic agent is a neurokinin antagonist.

20. A method of treating irritable bowel syndrome or emesis, which comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound according to claim 1 or 3 .

21. A method according to claim 20 for treating irritable bowel syndrome.

22. A method according to claim 20 for treating emesis.

Assignments (10)
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 7541537 PREVIOUSLY RECORDED AT REEL: 034045 FRAME: 0951. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded Aug 14, 2018
From: ALBANY MOLECULAR RESEARCH, INC.; ALO ACQUISITION LLC; AMRI BURLINGTON, INC.; AMRI RENSSELAER, INC.; CEDARBURG PHARMACEUTICALS, INC.; OSO BIOPHARMACEUTICALS MANUFACTURING, LLC
To: BARCLAYS BANK PLC, AS THE COLLATERAL AGENT
Reel/Frame 046796/0352 →
RELEASE OF SECURITY INTEREST Recorded Aug 31, 2017
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: ALBANY MOLECULAR RESEARCH, INC.; ALO ACQUISITION LLC; AMRI BURLINGTON, INC.; AMRI RENSSELAER, INC.; CEDARBURG PHARMACEUTICALS, INC.; OSO BIOPHARMACEUTICALS MANUFACTURING, LLC; AMRI SSCI, LLC; EUTICALS INC.
Reel/Frame 043742/0085 →
SECURITY INTEREST Recorded Oct 24, 2014
From: ALBANY MOLECULAR RESEARCH, INC.; ALO ACQUISITION LLC; AMRI BURLINGTON, INC.; AMRI RENSSELAER, INC.; CEDARBURG PHARMACEUTICALS, INC.; OSO BIOPHARMACEUTICALS MANUFACTURING, LLC
To: BARCLAYS BANK PLC, AS THE COLLATERAL AGENT
Reel/Frame 034045/0951 →
RELEASE OF SECURITY INTEREST Recorded Jul 9, 2014
From: WELLS FARGO
To: ALBANY MOLECULAR RESEARCH, INC.
Reel/Frame 033283/0357 →
SECURITY AGREEMENT Recorded Apr 20, 2012
From: ALBANY MOLECULAR RESEARCH, INC.; AMRI BURLINGTON, INC.; AMRI BOTHELL RESEARCH CENTER, INC.; AMRI RENESSELAER, INC.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION
Reel/Frame 028078/0227 →
TERMINATION Recorded Apr 19, 2012
From: BANK OF AMERICA, N.A.
To: ALBANY MOLECULAR RESEARCH, INC.; AMRI BOTHELL RESEARCH CENTER, INC.; AMRI BURLINGTON, INC.; AMRI RENESSELAER, INC.
Reel/Frame 028072/0335 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jun 6, 2011
From: ALBANY MOLECULAR RESEARCH, INC.; AMRI RENSSELAER, INC.; AMRI BOTHELL RESEARCH CENTER, INC.; AMRI BURLINGTON, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 026397/0001 →
MERGER Recorded Feb 8, 2010
From: AMR TECHNOLOGY, INC.
To: ALBANY MOLECULAR RESEARCH, INC.
Reel/Frame 023905/0317 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2009
From: AMR TECHNOLOGY, INC.
To: ALBANY MOLECULAR RESEARCH, INC.
Reel/Frame 022092/0512 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 7, 2006
From: FAIRFAX, DAVID J.; YANG, ZHICAI
To: AMR TECHNOLOGY, INC.
Reel/Frame 017264/0525 →